UNSPSC 51291603: Dimetacrine bitartrate

This classification denotes an antidepressant agent with the molecular formula C20H26N2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DVH164X0IF, chemically known as acridan, 10-(3-(dimethylamino)propyl)-9,9-dimethyl-, tartrate (1:1), but more generally known as dimetacrine bitartrate, which bears US NIH Compound Identifier 94279. European Medicines Agency schedules dimetacrine bitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07168MIG.

Most nations, for tariff purposes, schedule dimetacrine bitartrate under HS 29339990. SMILES: CC1(C2CCCCC2N(C3C1CCCC3)CCCN(C)C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51291603 Dimetacrine bitartrate is a Commodity code that in practice covers pharmaceutical products and related health-delivery supplies procured by state and local health agencies, though recent opportunities tagged under this code show limited direct alignment with the specific active ingredient. The recent solicitation activity captures a broader pharmaceutical and health-system procurement landscape: Seminole County, Florida's IFB for naloxone and drug deactivation systems reflects county public-health purchasing; the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs signals state-level pharmacy-benefit restructuring; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products demonstrates cooperative purchasing of commodity pharmaceuticals across state and local jurisdictions. These opportunities indicate that state and local governments use pharmaceutical codes both for urgent public-health response procurement (overdose reversal agents) and for ongoing supply-chain management of generic drugs through established distribution networks and cooperative vehicles.

Recent opportunities span Florida, Texas, and Minnesota through a mix of county health departments, state health commissions, and multistate cooperative purchasing alliances. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a response deadline of July 26, 2023. Texas HHS issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct pharmaceutical manufacturer relationships outside traditional pharmacy benefit managers and wholesalers. The Minnesota Department of Administration's MMCAP released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with responses due March 26, 2026, and contract effectiveness July 1, 2026. The code shows activity in public-health emergency response, state pharmacy benefit redesign, and cooperative purchasing of commodity pharmaceuticals, though no single recent opportunity directly references dimetacrine bitartrate by name.